Key Takeaways Amarin surged 27.3% after licensing Vazkepa to Recordati for commercialization across 59 EU countries. The deal includes $25M upfront, up to $150M in milestones, and supply-based royalty revenues. AMRN expects $70M in EU cost savings over 12 months as part of a broader strategy to fuel growth.Shares of Amarin (AMRN) jumped 27.3% on Tuesday after the company announced that it has signed an exclusive long-term license and supply agreement with Italy-based Recordati to commercialize its sole ma ...

Amarin (AMRN) shares rallied 27.3% in the last trading session to close at $16.04. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 13.4% gain over the past four weeks.The stock surged 27% after Amarin licensed EU rights to Vazkepa to Italy-based Recordati, securing $25M upfront, up to $150M in milestones, and ongoing royalties. The deal significantly expands Vazkepa’s market reach while cutting EU-related cos ...

Amarin Corporation (AMRN) Update / Briefing June 24, 2025 09:00 AM ET Speaker0 Welcome to Amarin Corporation's Conference Call. I would like to turn the conference call over to Mark Marmer, Vice President, Corporate Communications and Investor Relations at Amarin. Speaker1 Good morning and good afternoon, everyone, and thank you for joining us. Please be aware that this conference call will contain forward looking statements that are intended to be covered under the Safe Harbor provided under federal securi ...

From a technical perspective, Amarin Corporation PLC (AMRN) is looking like an interesting pick, as it just reached a key level of support. AMRN's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.A golden cross is a technical chart pattern that can signify a potential bullish breakout. It's formed from a crossover involving a security's short-term moving average breaking above a longer-term moving average, with the most com ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Amarin (AMRN) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Amarin is one of 998 companies in the Medical group. The Medical group currently sits at #6 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks R ...

Amarin (AMRN) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Individual ...

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, June 10th:Amarin Corporation plc (AMRN) : This pharmaceuticals company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 50% over the last 60 days.Amarin’s shares gained 31.1% over the last three months compared with the S&P 500’s advance of 7.7%. The company possesses a Momentum Score  of A.Comfort Systems USA, Inc. (FIX) : This mechanical and electr ...

行业概况 - 医疗行业包含997只个股 当前Zacks行业排名为第4位(共16个行业组别) [2] - 医疗-生物医学和遗传学子行业包含505只个股 当前Zacks子行业排名第73位 [6] GSK表现分析 - 年初至今股价回报率达15.9% 显著跑赢医疗行业平均-6.5%的跌幅 [4] - 当前Zacks评级为买入级(2) 过去季度全年盈利预测共识值上调5.5% [3] - 在生物医学子行业中表现优异 该子行业平均跌幅为5.4% [6] Amarin对比分析 - 年初至今回报率16.4% 略高于GSK且大幅超越行业平均 [4] - 当前Zacks评级同为买入级(2) 过去3个月EPS预测共识值大幅上调34.8% [5] - 与GSK同属生物医学子行业 均呈现逆势上涨特征 [6] 投资关注点 - GSK和Amarin作为医疗板块领涨股 有望延续强势表现 [7] - 两家公司盈利预测持续上调 反映分析师情绪改善 [3][5]

Amarin Corporation (AMRN) reported a loss of 4 cents per share for the first quarter of 2025, which was significantly narrower than the Zacks Consensus Estimate of a loss of $1.12. The company had reported a loss of 2 cents per share in the year-ago quarter.Excluding stock-based compensation expense and the American Depositary Shares (“ADS”) ratio change fees, the company incurred an adjusted loss of 2 cents per share in the first quarter of 2025 compared with an adjusted loss of 1 cent reported in the year ...

Amarin Corporation (AMRN) Q1 2025 Earnings Call May 07, 2025 08:00 AM ET Company Participants Mark Marmur - VP, Global Corporate Comunications & IRAaron Berg - CEO, President & DirectorPeter Fishman - SVP & CFOAdam Ferrarini - Biotech Equity Research AssociateSteven Ketchum - Executive VP, President of Research & Development and Chief Scientific Officer Conference Call Participants None - Analyst Operator Welcome to Amarin Corporation's conference call to discuss its first quarter twenty twenty five busines ...